NCT00471081已完成2 期
Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 385
- 试验地点
- 20
- 主要终点
- Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y) Antibody Titers Greater Than or Equal to the Cut-off Value
研究概览
简要总结
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.
详细描述
The protocol posting has been amended to reflect changes as a consequence of an amendment to the protocol and also to comply with the FDA amendment Act, Sep 2007. Sections impacted are Brief Title, Official Title of the study, Brief Summary, Key Inclusion & Exclusion criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 9 Months 至 9 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects whose parents/guardians the investigator believes can and will comply with the requirements of the protocol
- •A male or female of 9 months of age (has not attained 10 months of age) at the time of enrollment.
- •Up to date on vaccinations based on ACIP recommendations and the standard practice at the investigational site.
- •Written informed consent obtained from parents/guardian of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding enrollment, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol within 1 month of a dose of study vaccine(s), with the exception of influenza vaccine.
- •Planned administration of a tetanus toxoid (TT) containing vaccine throughout the active phase of the study (through one month after the last vaccination).
- •Previous vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, C W and/or Y.
- •History of meningococcal diseases.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing is required).
- •A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
- •History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
- •Major congenital defects or serious chronic illness.
- •History of any neurologic disorders or seizures.
- •Acute disease at the time of enrollment.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the active phase of the study (through one month after the last dose of study vaccine).
研究组 & 干预措施
Group A
Experimental
Single dose GSK134612.
干预措施: Meningococcal vaccine GSK134612 (Biological)
Group B
Experimental
Two doses of GSK134612.
干预措施: Meningococcal vaccine GSK134612 (Biological)
结局指标
主要结局
Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y) Antibody Titers Greater Than or Equal to the Cut-off Value
时间窗: One month after the last dose (at Month 4)
The cut-off value for the hSBA titers was greater than or equal to (≥) 1:8.
次要结局
- Number of Subjects With Serum Bactericidal Assay Using hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers Greater Than or Equal to the Cut-off Value(At Month 1 (for GSK 134612 2 doses Group only) and Month 4)
- hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers(At Month 1 (for GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers Greater Than or Equal to the Cut-off Value(At Month 1 (for GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Serum Bactericidal Assay Using rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Greater Than or Equal to the Cut-off Value(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- rSBA-MenA, rSBA-MenC, rSBA-MenW -135 and rSBA-Men-Y Antibody Titers(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Anti-polysaccharide Meningococcal Serogroup A (Anti-PSA), Serogroup C (Anti-PSC), Serogroup W-135 (Anti-PSW-135) and Serogroup Y (Anti-PSY) Antibody Concentrations Greater Than or Equal to the Cut-off Value(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Greater Than or Equal to the Cut-off Value(At Month 1 (GSK 134612 s doses Group only) and Month 4)
- Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations(At Month 1 (GSK 134612 2 doses Group only) and Month 4)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms(During the 4-day (Days 0-3) and 8-day (Days 0-7) periods following each vaccination)
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(During the 4-day (Days 0-3) and 8-day (Days 0-7) periods following each vaccination)
- Number of Subjects With Any Unsolicited Adverse Events (AEs)(Up to 1 month post-vaccination)
- Number of Subjects With Serious Adverse Events (SAEs)(Up to study end (Month 9))
- Number of Subjects With New Onset Chronic Ilnesses (NOCI)(Up to study end (Month 9))
- Number of Subjects Reporting Rash(Up to study end (Month 9))
- Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits(Up to study end (Month 9))
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.Infections, MeningococcalNCT00454909GlaxoSmithKline873
已完成
2 期
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in ChildrenVirus DiseasesNCT02548078GlaxoSmithKline600
已完成
3 期
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionInfections, StreptococcalStreptococcus Pneumoniae VaccinesNCT01746108GlaxoSmithKline52
已完成
1 期
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With FluarixInfluenzaNCT00693706GlaxoSmithKline200
已完成
3 期
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in MaliInfections, StreptococcalNCT00985465GlaxoSmithKline218